ArticlePloS one2007
Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.Current opinion in HIV and AIDS · 2022Review
- People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells.Scientific reports · 2022Article
- Review
- Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.Progress in lipid research · 2021Review
- Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke.Acta neurologica Scandinavica · 2021Article
- Observational
- Review
- Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120-mediated brain inflammation.Journal of neuroinflammation · 2014Article
- Article
- Systems biology unravels interferon responses to respiratory virus infections.World journal of biological chemistry · 2014Review
- C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.Applied & translational genomics · 2013Review
- In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4.AIDS research and therapy · 2013Article
- Targeting tumor cell metabolism with statins.Oncogene · 2012Review
- Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- [CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach].Antibiotiques (Paris, France : 1999) · 2010Article
- Article
- Lipids in host-pathogen interactions: pathogens exploit the complexity of the host cell lipidome.Progress in lipid research · 2010Review
- Update on statin-mediated anti-inflammatory activities in atherosclerosis.Seminars in immunopathology · 2009 · on this mapReview
- HIV entry in macrophages is dependent on intact lipid rafts.Virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins have previously been shown to reduce the in vitro infection of human immunodeficiency virus type 1 (HIV-1) through modulation of Rho GTPase activity and lipid raft formation at the cell surface, as well as by disrupting LFA-1 incorporation into viral particles. PRINCIPLE
findingsHere we demonstrate that treatment of an enriched CD4(+) lymphocyte population with lovastatin (Lov), mevastatin (Mev) and simvastatin (activated and non-activated, Sim(A) and Sim(N), respectively) can reduce the cell surface expression of the CC-chemokine receptor CCR5 (P<0.01 for Sim(A) and Lov). The lowered CCR5 expression was associated with down-regulation of CCR5 mRNA expression. The CC-chemokine RANTES protein and mRNA expression levels were slightly increased in CD4(+) enriched lymphocytes treated with statins. Both R5 and X4 HIV-1 were reduced for their infection of statin-treated cells; however, in cultures where statins were removed and where a decrease in CCR5 expression was observed, there was a preferential inhibition of infection with an R5 versus X4 virus.
conclusionsThe results indicate that the modulation of CC-chemokine receptor (CCR5) and CC-chemokine (RANTES) expression levels should be considered as contributing to the anti-viral effects of statins, preferentially inhibiting R5 viruses. This observation, in combination with the immunomodulatory activity exerted by statins, suggests they may possess more potent anti-HIV-1 activity when applied during the early stages of infection or in lowering viral transmission. Alternatively, statin treatment could be considered as a way to modulate immune induction such as during vaccination protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.